News

Merck announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance viral and gene therapy products has completed both a U.S. Food & Drug…
Read More...

Agenus announced the launch of a subsidiary company for its cell therapy business, AgenTus Therapeutics, Inc. The subsidiary is focused on realizing significant value for both…
Read More...

Eli Lilly and Company announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing…
Read More...

TiGenix NV, an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for…
Read More...

Titan Pharmaceuticals, Inc. announced the planned presentation of non-clinical data on the use of its ProNeura™ subdermal implant for the long-term, sustained delivery of liothyronine…
Read More...

Astellas Pharma Inc. and Universal Cells, Inc. announced that Astellas Institute for Regenerative Medicine ("AIRM") and Universal Cells have entered into an exclusive worldwide license…
Read More...

Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that the US Food and Drug Administration (FDA) granted marketing…
Read More...

Teva Pharmaceutical announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related…
Read More...

Amgen and Boston Children's Hospital announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses.…
Read More...

Exelixis announced that the U.S. Food and Drug Administration (FDA) has determined the company’s supplemental New Drug Application (sNDA) for CABOMETYX®(cabozantinib) for patients with…
Read More...

Takeda Pharmaceutical Company Limited and HemoShear Therapeutics announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic…
Read More...

GSK announced that the World Health Organization (WHO) has awarded prequalification for the new four-dose vial presentation of Synflorix pneumococcal vaccine targeted mainly for…
Read More...

Miraca Life Sciences continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a…
Read More...

Ionis Pharmaceuticals, Inc. announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPTRx in patients with mild Alzheimer's disease (AD). Ionis earned a $10 million…
Read More...

TARGET PharmaSolutions announced that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement.  Bristol-Myers Squibb is committed to…
Read More...

Flex Pharma announced that, under its open investigational new drug (IND) application, the Company has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial…
Read More...

CordenPharma has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is…
Read More...

AcelRx Pharmaceuticals announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for DSUVIA™ …
Read More...

Otsuka Pharmaceutical and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with…
Read More...

Merz and Teijin Limited announced that they have entered into a strategic license and co-development agreement for the commercialization of Xeomin (incobotulinumtoxinA) for Japan.…
Read More...